Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

789
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Mutations01:39

Mutations

66.2K
Overview
66.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracking <i>kdr</i> alleles associated with pyrethroid resistance in <i>Aedes albopictus</i> across Italy: a nationwide genotypic dataset by MosqIRIT network.

GigaByte (Hong Kong, China)·2026
Same author

Unique Imaging Findings of a Calvarial Ossifying Fibroma Successfully Managed With Surgery and Definitive Intent Radiotherapy.

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2026
Same author

Inter-centre heterogeneity, temporal evolution, and factors associated with treatment selection and outcomes in chronic inflammatory demyelinating polyradiculoneuropathy: a multicentre, combined prospective and retrospective observational study.

EClinicalMedicine·2026
Same author

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

The Lancet. Child & adolescent health·2026
Same author

Early Clinical, Imaging, and Pathological Characteristics of SRPK3/TTN-Digenic Myopathy.

Annals of clinical and translational neurology·2026
Same author

Newborn screening for spinal muscular atrophy: time is motor neuron.

Nature reviews. Neurology·2026

Related Experiment Video

Updated: Apr 21, 2026

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
05:12

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Published on: September 4, 2017

10.0K

PDCD10 gene mutations in multiple cerebral cavernous malformations.

Maria Sole Cigoli1, Francesca Avemaria1, Stefano De Benedetti1

  • 1Department of Laboratory Medicine, Medical Genetics Unit - Niguarda Ca' Granda Hospital, Milan, Italy.

Plos One
|October 30, 2014
PubMed
Summary

Genetic mutations in PDCD10/CCM3 cause hereditary cerebral cavernous malformations (CCMs). This study identified novel PDCD10/CCM3 mutations in Italian families, revealing an earlier onset of CCM symptoms compared to other genetic forms.

More Related Videos

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

7.9K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

2.3K

Related Experiment Videos

Last Updated: Apr 21, 2026

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
05:12

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Published on: September 4, 2017

10.0K
A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

7.9K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

2.3K

Area of Science:

  • Genetics
  • Neurology
  • Vascular Biology

Background:

  • Cerebral cavernous malformations (CCMs) are vascular abnormalities.
  • CCMs can lead to seizures, hemorrhages, and neurological deficits.
  • Familial CCMs follow autosomal dominant inheritance with variable expression.

Purpose of the Study:

  • To investigate PDCD10/CCM3, a gene responsible for 10-15% of hereditary CCMs.
  • To identify and characterize PDCD10/CCM3 mutations in Italian CCM families.
  • To explore genotype-phenotype correlations in PDCD10/CCM3-related CCMs.

Main Methods:

  • Direct sequencing and MLPA analysis of 87 Italian CCM patients.
  • Investigated familial and multiple CCM cases.
  • Compared clinical manifestations between CCM1/CCM2 and PDCD10/CCM3 mutated patients.

Main Results:

  • Mutations identified in over 97.7% of investigated individuals.
  • PDCD10/CCM3 mutations accounted for 13.1% of hereditary CCM cases.
  • Four novel and four known PDCD10/CCM3 mutations were discovered; patients showed earlier symptom onset.

Conclusions:

  • PDCD10/CCM3 is a significant gene in hereditary CCMs, particularly in the Italian population.
  • PDCD10/CCM3 mutations are associated with an earlier onset of clinical symptoms.
  • Further research and clinical follow-up are needed to establish a characteristic PDCD10/CCM3 phenotype.